Binimetinib and encorafenib combination therapy cannot be used on people with what type of melanoma?

• A. Wild-type BRAF melanoma
• B. BRAF V600E melanoma
• C. BRAF V600K melanoma
• D. NRAS-mutant melanoma

Answer: (A)

This treatment combination is designed to target melanomas driven by activating BRAF mutations, such as V600E or V600K, by blocking the BRAF protein and downstream MEK to shut down MAPK signaling and slow tumor growth. In melanomas with wild-type (non-mutated) BRAF, a BRAF inhibitor can paradoxically activate the MAPK pathway in some cells, potentially promoting tumor growth and causing adverse effects. Because there is no BRAF mutation to target, using this regimen in wild-type BRAF melanoma is not appropriate. While BRAF-mutant forms like V600E or V600K are the intended targets, NRAS-mutant melanomas do not involve BRAF mutations and are not treated with this combo.